Find a Clinical Trial

Showing 71 - 80 of 238 Trials

RINGSIDE: A Phase 2/3, Randomized, Multicenter Study toEvaluate AL102 in Patients with Progressing Desmoid Tumors

Principal Investigator:

Prabhjot Singh Mundi, MD

Contact Number:

212-342-5162

NCT Number:

NCT04871282

Population:

Adult

Phase:

II/III

You are being asked to participate in this study because you have been diagnosed with a progressive desmoid tumor. The purpose of this study is to see if the study drug, called AL102 (referred to from now on as the “study drug”), is safe and effective in people with progressive desmoid tumors. The study will also look at how your body responds to the study drug and how your body processes the drug . The study drug works by stopping a chemical pathway in the cells that allows desmoid tumors to grow. It is hoped that by stopping this pathway the study drug will stop desmoid tumor...
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

Principal Investigator:

Mark N. Stein, MD

Contact Number:

212-342-5162

NCT Number:

NCT03866382

Population:

Adult

Phase:

II

This purpose of this study is to test the effectiveness of cabozantinib with nivolumab and ipilimumab in rare genitourinary cancers that have no standard treatment options. Are you Eligible? (Inclusion Criteria) Do you have confirmed diagnosis of one of the following cancers? -small cell carcinoma of the bladder; -adenocarcinoma of the bladder; -squamous cell carcinoma of the bladder; -plasmacytoid urothelial carcinoma; -any penile cancer; -sarcomatoid renal cell carcinoma; -sarcomatoid urothelial carcinoma; -renal medullary carcinoma or other miscellaneous histologic variants of the...
A SINGLE ARM, MULTICENTER, PHASE II, OPEN-LABEL TRIAL TO EVALUATE EFFICACY OF ISATUXIMAB IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE

Principal Investigator:

Divaya Bhutani, MD

Contact Number:

212-342-5162

NCT Number:

NCT04614558

Population:

Adult

Phase:

II

The purpose of this study is to see whether Isatuximab can help improve kidney function of participants with Monoclonal Gammopathy of Renal Significance (MGRS). Isatuximab is approved by the Food and Drug Administration (FDA) for the treatment of adult patients with multiple myeloma, but it is not approved by the FDA to treatMonoclonal Gammopathy of Renal Significance (MGRS). This means that the use of isatuximab in this study is considered ‘investigational’. Are you Eligible? (Inclusion Criteria) • Are you 18 years of age or older? • Do you have persistent renal...
AREN1921: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Principal Investigator:

Nobuko Hijiya, MD

Contact Number:

212-342-5162

NCT Number:

NCT04322318

Population:

Pediatrics/Adult

Phase:

II

This is a Phase 2 study of patients for the treatment of patients with high risk Wilms tumors (including those with diffuse anaplastic Wilms tumor- DAWT) and those who have relapsed favorable histology Wilms tumor (FHWT). The main goal of the study is to find out whether treatment with chemotherapy consisting of vincristine/irinotecan; cyclophosphamide/carboplatin/etoposide; and vincristine/doxorubicin/cyclophosphamide) improves the survival of patients with newly diagnosed Stage 4 diffuse anaplastic Wilms tumor (DAWT) or Standard-Risk relapsed favorable histology Wilms tumor (SRrFHWT) as...
AALL1821: A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/=1 to <31 Years Old with First Relapse

Principal Investigator:

Nobuko Hijiya, MD

Contact Number:

212-342-5162

NCT Number:

NCT04546399

Population:

Pediatrics/Adult

Phase:

II

This is a study looking at how well the combination treatment of Blinatumomab and Nivolumab works in patients with first relapse of B-cell Acute Lymphoblastic Leukemia (B-ALL) as compared to treatment with only Blinatumomab. In addition, it is looking at what effects, good and/or bad the treatment has. First relapse means that B-ALL has come back after the initial treatment a patient received for B-ALL. All patients will receive treatment with Blinatumomab, an antibody (protein) that targets a marker on B-ALL cells and then uses your immune system to kill the B-ALL cell. Some patients will...
Audiovisual Didactic Experience for Latino patient treatment Adherence and Non-English speaker Trial Enrollment (ADELANTE) Study in Radiation Oncology

Principal Investigator:

Lisa Ann Kachnic, MD, FASTRO

Contact Number:

212-342-5162

NCT Number:

NCT05351424

Population:

Adult

Phase:

II

In this study, you will be randomized to receive either a brochure or watch a video that discusses radiation and cancer clinical trials. In addition, you will complete questionnaires at seven time points: 1 questionnaire before radiotherapy, 4 questionnaires during the course of radiotherapy and 2 questionnaires at follow-up visits. The questionnaires and brochure or video administration will take place during your standard of care visits. Are you Eligible? (Inclusion Criteria) To be included in the main study, you must: 1. be age 18 years or older 2. be Spanish speaker of Latino Background...
A randomized phase II study of CHO(E)P vs CC-486-CHO(E)P vs duvelisib-CHO(E)P in previously untreated CD30 negative peripheral T-cell lymphomas

Principal Investigator:

Jennifer Effie Amengual, MD

Contact Number:

212-342-5162

NCT Number:

NCT04803201

Population:

Pediatrics/Adult

Phase:

II

The purpose of this study is to compare the usual treatment alone to using duvelisib or CC-486 plus the usual treatment for patients with peripheral T-cell lymphoma. The usual approach for patients who are not in a study is treatment with the FDA approved chemotherapy regimens used in this trial (CHOP or CHOEP) without the addition of the study drugs duvelisib or CC-486 (azacitidine). The addition of duvelisib or CC-486 (azacitidine) to the usual treatment may or may not increase the chance of cancer going into remission. But, it could also cause side effects, which the study doctors want to...
An open-label phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL)

Principal Investigator:

Fabio M. Iwamoto, MD

Contact Number:

212-342-5162

NCT Number:

NCT04947319

Population:

Adult

Phase:

II

The purpose of this study is to learn the effects of the investigational new drug, tirabrutinib, when given for the treatment of PCNSL. “Investigational new drug” means a drug that has not been approved as a marketed product (that is, available to be prescribed or sold) by the United States (US) Food and Drug Administration (FDA). Tirabrutinib acts by blocking an enzyme called Bruton’s tyrosine kinase or BTK. Some cancer cells use BTK to grow and thrive in your body. Tirabrutinib blocks BTK and may interfere with the growth of cancer cells. This study is divided into 2 parts...
A Phase 2, Open-Label, Multicenter, Randomized Study Evaluating neoadjuvant therapy targeting the Adenosine immunosuppressive pathway in combination with Immune checkpoint blockade and Radiation Therapy in Patients with advanced PANCreatic Ductal

Principal Investigator:

Gulam A. Manji, MD

Contact Number:

212-342-5162

NCT Number:

NCT06048484

Population:

Adult

Phase:

II

The main goal of this study is to find out if treatment with zimberelimab and stereotactic body radiation therapy alone or in combination with quemliclustat, with or without etrumadenant, given before surgery is safe and if it can further increase the immune response against the tumor. Are you Eligible? (Inclusion Criteria) You must have been diagnosed with advanced pancreatic adenocarcinoma. -You must be comfortable receiving study drug through a vein in your arm (intravenously). -You must be willing to undergo surgery.
A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ADJUVANT AUTOGENE CEVUMERAN PLUS ATEZOLIZUMAB AND mFOLFIRINOX VERSUS mFOLFIRINOX ALONE IN PATIENTS WITH RESECTED PANCREATIC DUCTAL ADENOCARCINOMA

Principal Investigator:

Gulam A. Manji, MD

Contact Number:

212-342-5162

NCT Number:

NCT05968326

Population:

Adult

Phase:

II

The purpose of this study is to compare the effects, good or bad, of autogene cevumeran plus atezolizumab and mFOLFIRINOX compared with mFOLFIRINOX (standard of care chemotherapy) alone on patients with resected pancreatic ductal adenocarcinoma (PDAC). In this study, the participant will get either the combination of autogene cevumeran plus atezolizumab and mFOLFIRINOX or mFOLFIRINOX alone. Autogene cevumeran is a personalized drug product that will be made specifically for the participant and is designed to activate and train your immune system to find and kill cancer cells. Autogene...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages